Search

Your search keyword '"Stevanovic, Katarina"' showing total 32 results
Start Over Author "Stevanovic, Katarina"

Refine your results

more »

more »

more »
32 results on '"Stevanovic, Katarina"'

1. Concepts for the Development of Person-Centered, Digitally Enabled, Artificial Intelligence–Assisted ARIA Care Pathways (ARIA 2024)

Author

Bousquet, Jean, Schünemann, Holger J., Sousa-Pinto, Bernardo, Zuberbier, Torsten, Togias, Alkis, Samolinski, Boleslaw, Bedbrook, Anna, Czarlewski, Wienczyslawa, Hofmann-Apitius, Martin, Litynska, Justyna, Vieira, Rafael José, Anto, Josep M., Fonseca, Joao A., Brozek, Jan, Bognanni, Antonio, Brussino, Luisa, Canonica, G. Walter, Cherrez-Ojeda, Ivan, Cruz, Alvaro A., Vecillas, Leticia de las, Dykewicz, Mark, Gemicioglu, Bilun, Giovannini, Mattia, Haahtela, Tari, Jacobs, Marc, Jacomelli, Cristina, Klimek, Ludger, Kvedariene, Violeta, Larenas-Linnemann, Desiree E., Louis, Gilles, Lourenço, Olga, Leemann, Lucas, Morais-Almeida, Mario, Neves, Ana Luisa, Nadeau, Kari C., Nowak, Artur, Palamarchuk, Yuliia, Palkonen, Susanna, Papadopoulos, Nikolaos G., Parmelli, Elena, Pereira, Ana Margarida, Pfaar, Oliver, Regateiro, Frederico S., Savouré, Marine, Taborda-Barata, Luis, Toppila-Salmi, Sanna K., Torres, Maria J., Valiulis, Arunas, Ventura, Maria Teresa, Williams, Sian, Yepes-Nuñez, Juan J., Yorgancioglu, Arzu, Zhang, Luo, Zuberbier, Jaron, Abdul Latiff, Amir Hamzah, Abdullah, Baharudin, Agache, Ioana, Al-Ahmad, Mona, Al-Nesf, Maryam Ali, Al Shaikh, Nada A., Amaral, Rita, Ansotegui, Ignacio J., Asllani, Julijana, Balotro-Torres, Maria Cristina, Bergmann, Karl-Christian, Bernstein, Jonathan A., Bindslev-Jensen, Carsten, Blaiss, Michael S., Bonaglia, Cristina, Bonini, Matteo, Bossé, Isabelle, Braido, Fulvio, Caballero-Fonseca, Fernan, Camargos, Paulo, Carreiro-Martins, Pedro, Casale, Thomas, Castillo-Vizuete, José-Antonio, Cecchi, Lorenzo, Teixeira, Maria do Ceu, Chang, Yoon-Seok, Loureiro, Claudia Chaves, Christoff, George, Ciprandi, Giorgio, Cirule, Ieva, Correia-de-Sousa, Jaime, Costa, Elisio M., Cvetkovski, Biljana, de Vries, Govert, Del Giacco, Stefano, Devillier, Philippe, Dokic, Dejan, Douagui, Habib, Durham, Stephen R., Enecilla, Maria Lourdes, Fiocchi, Alessandro, Fokkens, Wytske J., Fontaine, Jean-François, Gawlik, Radoslaw, Gereda, Jose E., Gil-Mata, Sara, Giuliano, Antonio F.M., Gotua, Maia, Gradauskiene, Brigita, Guzman, Maria Antonieta, Hossny, Elham, Hrubiško, Martin, Iinuma, Tomohisa, Irani, Carla, Ispayeva, Zhanat, Ivancevich, Juan Carlos, Jartti, Tuomas, Jeseňák, Miloš, Julge, Kaja, Jutel, Marek, Kaidashev, Igor, Bennoor, Kazi S., Khaltaev, Nicolai, Kirenga, Bruce, Kraxner, Helga, Kull, Inger, Kulus, Marek, Kuna, Piotr, Kupczyk, Maciej, Kurchenko, Andriy, La Grutta, Stefania, Lane, Stephen, Miculinic, Neven, Lee, Sang Min, Le Thi Tuyet, Lan, Lkhagvaa, Battur, Louis, Renaud, Mahboub, Bassam, Makela, Mika, Makris, Michael, Maurer, Marcus, Melén, Eric, Milenkovic, Branislava, Mohammad, Yousser, Moniuszko, Marcin, Montefort, Stephen, Moreira, Andre, Moreno, Pablo, Mullol, Joaquim, Nadif, Rachel, Nakonechna, Alla, Navarro-Locsin, Cecilia Gretchen, Neffen, Hugo E., Nekam, Kristof, Niedoszytko, Marek, Nunes, Elizabete, Nyembue, Dieudonné, O’Hehir, Robyn, Ollert, Markus, Ohta, Ken, Okamoto, Yoshitaka, Okubo, Kimihiro, Olze, Heidi, Padukudru, Mahesh Anand, Palomares, Oscar, Pali-Schöll, Isabella, Panzner, Petr, Palosuo, Kati, Park, Hae S., Passalacqua, Giovanni, Patella, Vincenzo, Pawankar, Ruby, Pétré, Benoît, Pitsios, Constantinos, Plavec, Davor, Popov, Todor A., Puggioni, Francesca, Quirce, Santiago, Raciborski, Filip, Ramonaité, Agné, Recto, Marysia, Repka-Ramirez, Susana, Roberts, Graham, Robles-Velasco, Karla, Roche, Nicolas, Rodriguez-Gonzalez, Monica, Romualdez, Joel A., Rottem, Menachem, Rouadi, Philip W., Salapatas, Marianella, Sastre, Joaquin, Serpa, Faradiba S., Sayah, Zineb, Scichilone, Nicola, Senna, Gianenrico, Sisul, Juan Carlos, Solé, Dirceu, Soto-Martinez, Manuel E., Sova, Milan, Sozinova, Olga, Stevanovic, Katarina, Ulrik, Charlotte Suppli, Szylling, Anna, Tan, Frances M., Tantilipikorn, Pongsakorn, Todo-Bom, Ana, Tomic-Spiric, Vesna, Tsaryk, Vladyslav, Tsiligianni, Ioanna, Urrutia-Pereira, Marilyn, Rostan, Marylin Valentin, Sofiev, Mikhail, Valovirta, Erkka, Van Eerd, Michiel, Van Ganse, Eric, Vasankari, Tuula, Vichyanond, Pakit, Viegi, Giovanni, Wallace, Dana, Wang, De Yun, Waserman, Susan, Wong, Gary, Worm, Margitta, Yusuf, Osman M., Zaitoun, Fares, and Zidarn, Mihaela

Published
2024
Full Text
View/download PDF

3. GA2LEN ANACARE consensus statement: Potential of omalizumab in food allergy management.

Author

Zuberbier, Torsten, Muraro, Antonella, Nurmatov, Ulugbek, Arasi, Stefania, Stevanovic, Katarina, Anagnostou, Aikaterini, Bonaguro, Roberta, Chinthrajah, Sharon, Lack, Gideon, Fiocchi, Alessandro, Le, Thuy‐My, Turner, Paul, Lozano, Montserrat Alvaro, Angier, Elizabeth, Barni, Simona, Bégin, Phillippe, Ballmer‐Weber, Barbara, Cardona, Victoria, Bindslev‐Jensen, Carsten, and Cianferoni, Antonella

Abstract

Immunoglobulin E (IgE)‐mediated food allergies are the most common type of food allergy, often causing rapid symptoms after exposure to allergens posing a serious health risk and a high impact on patient's and caregiver's quality of life. Omalizumab, a humanized anti‐IgE monoclonal antibody, reduces allergic reactions by binding to circulating IgE. Omalizumab has been successfully used in allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, and was recently approved for treating IgE‐mediated food allergies by the US Food and Drug Administration (FDA). This GA2LEN ANACARE Consensus Statement presents our position on the use of omalizumab for treating IgE‐mediated food allergies, based on a systematic review and meta‐analysis, experience with use for other conditions, and expert consensus achieved via an eDelphi process. Following publication of the recent OUtMATCH study (stage 1) results and subsequent FDA approval, we propose that there is now sufficient evidence to recommend omalizumab as the only drug currently available that can mechanistically reduce IgE‐mediated food allergic reactions. We acknowledge that the evidence does not reach the highest level of evidence which would be needed for a guideline recommendation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

5. Green roof gardens – Selecting allergy friendly vegetation: a GA2LEN position paper

Author

Zuberbier, Torsten, primary, Stevanovic, Katarina, additional, Ansotegui, Ignacio J., additional, Anto, Josep M., additional, Bergmann, Karl-Christian, additional, D’Amato, Gennaro, additional, Grüntuch-Ernst, Almut, additional, Haahtela, Tari, additional, Maurer, Marcus, additional, Pietikäinen, Sirpa, additional, Christou, Demetrios, additional, and Bousquet, Jean, additional

Published
2023
Full Text
View/download PDF

6. A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative

Author

Zuberbier, Torsten, primary, Abdul Latiff, Amir, additional, Aggelidis, Xenofon, additional, Augustin, Matthias, additional, Balan, Radu‐Gheorghe, additional, Bangert, Christine, additional, Beck, Lisa, additional, Bieber, Thomas, additional, Bernstein, Jonathan A., additional, Bertolin Colilla, Marta, additional, Berardi, Alejandro, additional, Bedbrook, Anna, additional, Bindslev‐Jensen, Carsten, additional, Bousquet, Jean, additional, de Bruin‐Weller, Marjolein, additional, Bruscky, Dayanne, additional, Buyuktiryaki, Betul, additional, Canonica, Giorgio Walter, additional, Castro, Carla, additional, Chanturidze, Natia, additional, Chong‐Neto, Herberto Jose, additional, Chu, Chia‐Yu, additional, Chularojanamontri, Leena, additional, Cork, Michael, additional, Criado, Roberta F. J., additional, Barredo, Laia Curto, additional, Custovic, Adnan, additional, Darsow, Ulf, additional, Emurlai, Arben, additional, de Pablo, Ana, additional, Del Giacco, Stefano, additional, Girolomoni, Giampiero, additional, Deleva Jovanova, Tanja, additional, Deleuran, Mette, additional, Douladiris, Nikolaos, additional, Duarte, Bruno, additional, Dubakiene, Ruta, additional, Eller, Esben, additional, Engel‐Yeger, Batya, additional, Ensina, Luis Felipe, additional, Filho, Nelson Rosario, additional, Flohr, Carsten, additional, Fomina, Daria, additional, Francuzik, Wojciech, additional, Galimberti, Maria Laura, additional, Giménez‐Arnau, Ana M., additional, Godse, Kiran, additional, Mortz, Charlotte Gotthard, additional, Gotua, Maia, additional, Hide, Michihiro, additional, Hoetzenecker, Wolfram, additional, Hunzelmann, Nicolas, additional, Irvine, Alan, additional, Jack, Carolyn, additional, Kanavarou, Ioanna, additional, Katoh, Norito, additional, Kinaciyan, Tamar, additional, Kocatürk, Emek, additional, Kulthanan, Kanokvalai, additional, Lapeere, Hilde, additional, Lau, Susanne, additional, Machado Forti Nastri, Mariana, additional, Makris, Michael, additional, Mansour, Eli, additional, Marsland, Alexander, additional, Morelo Rocha Felix, Mara, additional, Moschione Castro, Ana Paula, additional, Nettis, Eustachio, additional, Nicolas, J. F., additional, Nosbaum, Audrey, additional, Odemyr, Mikaela, additional, Papapostolou, Niki, additional, Parisi, Claudio A. S., additional, Paudel, Sushil, additional, Peter, Jonny, additional, Pokharel, Prakash, additional, Puig, Luis, additional, Quint, Tamara, additional, Ramon, German Dario, additional, Regateiro, Frederico, additional, Ricci, Giampaolo, additional, Rosario, Cristine, additional, Sackesen, Cansin, additional, Schmid‐Grendelmeier, Peter, additional, Serra‐Baldrich, Esther, additional, Siemens, Kristina, additional, Smith, Cathrine, additional, Staubach, Petra, additional, Stevanovic, Katarina, additional, Su‐Kücük, Özlem, additional, Sussman, Gordon, additional, Tavecchio, Simona, additional, Teovska Mitrevska, Natasa, additional, Thaci, Diamant, additional, Toubi, Elias, additional, Traidl‐Hoffmann, Claudia, additional, Treudler, Regina, additional, Vadasz, Zahava, additional, van Hofman, Ingrid, additional, Ventura, Maria Teresa, additional, Wang, Zhao, additional, Werfel, Thomas, additional, Wollenberg, Andreas, additional, Yang, Ariana, additional, Weng Yew, Yik, additional, Zhao, Zuotao, additional, Zwiener, Ricardo, additional, and Worm, Margitta, additional

Published
2023
Full Text
View/download PDF

7. UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan

Author

Bousquet, Jean, primary, Samolinski, Boleslaw, additional, Kaidashev, Igor, additional, Maurer, Marcus, additional, Roche, Nicolas, additional, Sousa‐Pinto, Bernardo, additional, Kurchenko, Andrii, additional, Stepanenko, Roman, additional, Tsaryk, Vladyslav, additional, Klimek, Ludger, additional, Ventura, Maria Teresa, additional, Bedbrook, Anna, additional, Czarlewski, Wienczyslawa, additional, Lysanets, Yuliia, additional, Kupczyk, Maciej, additional, Skolimowski, Łukasz, additional, Kulus, Marek, additional, Del Giacco, Stefano, additional, Ollert, Markus, additional, Garcia‐Aymerich, Judith, additional, Robalo Cordeiro, Carlos, additional, Yorgancioglu, Arzu, additional, Schlapbach, Christoph, additional, Amaral, Rita, additional, Bonaglia, Cristina, additional, Bossé, Isabelle, additional, Buquicchio, Rosalba, additional, Christou, Demetrios, additional, Fedoruk, Galyna, additional, Fontanesi, Pietro, additional, Gemicioglu, Bilun, additional, Giuliano, Antonio F. M., additional, Lepore, Paolo, additional, Nakonechna, Alla, additional, Neisinger, Sophia, additional, Pereira, Ana M., additional, Ramanauskaite, Aiste, additional, Raciborski, Filip, additional, Sitkauskiene, Brigita, additional, Sokhatska, Oksana, additional, Stepanenko, Viktor, additional, Stevanovic, Katarina, additional, Syzon, Orysya, additional, Kvedariene, Violeta, additional, de Vries, Govert, additional, van Eerd, Michiel, additional, Valiulis, Arunas, additional, Fonseca, Joao A., additional, Anto, Josep M., additional, Haahtela, Tari, additional, Schünemann, Holger, additional, and Zuberbier, Torsten, additional

Published
2023
Full Text
View/download PDF

8. A concept for integrated care pathways for atopic dermatitis- a GA2LEN ADCARE initiative

Author

Büyüktiryaki, Ayşe Betül (ORCID 0000-0003-1206-969X & YÖK ID 195944); Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219); Saçkesen, Cansın (ORCID 0000-0002-1115-9805 & YÖK ID 182537), Zuberbier, Torsten; Abdul Latiff, Amir; Aggelidis, Xenofon; Augustin, Matthias; Balan, Radu-Gheorghe; Bangert, Christine; Beck, Lisa; Bieber, Thomas; Bernstein, Jonathan A.; Bertolin Colilla, Marta; Berardi, Alejandro; Bedbrook, Anna; Bindslev-Jensen, Carsten; Bousquet, Jean; de Bruin-Weller, Marjolein; Bruscky, Dayanne; Canonica, Giorgio Walter; Castro, Carla; Chanturidze, Natia; Chong-Neto, Herberto Jose; Chu, Chia-Yu; Chularojanamontri, Leena; Cork, Michael; Criado, Roberta F. J.; Barredo, Laia Curto; Custovic, Adnan; Darsow, Ulf; Emurlai, Arben; de Pablo, Ana; Del Giacco, Stefano; Girolomoni, Giampiero; Deleva Jovanova, Tanja; Deleuran, Mette; Douladiris, Nikolaos; Duarte, Bruno; Dubakiene, Ruta; Eller, Esben; Engel-Yeger, Batya; Ensina, Luis Felipe; Rosario Filho, Nelson; Flohr, Carsten; Fomina, Daria; Francuzik, Wojciech; Galimberti, Maria Laura; Gimenez-Arnau, Ana M.; Godse, Kiran; Mortz, Charlotte Gotthard; Gotua, Maia; Hide, Michihiro; Hoetzenecker, Wolfram; Hunzelmann, Nicolas; Irvine, Alan; Jack, Carolyn; Kanavarou, Ioanna; Katoh, Norito; Kinaciyan, Tamar; Kulthanan, Kanokvalai; Lapeere, Hilde; Lau, Susanne; Machado Forti Nastri, Mariana; Makris, Michael; Mansour, Eli; Marsland, Alexander; Morelo Rocha Felix, Mara; Moschione Castro, Ana Paula; Nettis, Eustachio; Nicolas, J. F.; Nosbaum, Audrey; Odemyr, Mikaela; Papapostolou, Niki; Parisi, Claudio A. S.; Paudel, Sushil; Peter, Jonny; Pokharel, Prakash; Puig, Luis; Quint, Tamara; Ramon, German Dario; Regateiro, Frederico; Ricci, Giampaolo; Rosario, Cristine; Schmid-Grendelmeier, Peter; Serra-Baldrich, Esther; Siemens, Kristina; Smith, Cathrine; Staubach, Petra; Stevanovic, Katarina; Su-Kucuk, Ozlem; Sussman, Gordon; Tavecchio, Simona; Teovska Mitrevska, Natasa; Thaci, Diamant; Toubi, Elias; Traidl-Hoffmann, Claudia; Treudler, Regina; Vadasz, Zahava; van Hofman, Ingrid; Ventura, Maria Teresa; Wang, Zhao; Werfel, Thomas; Wollenberg, Andreas; Yang, Ariana; Weng Yew, Yik; Zhao, Zuotao; Zwiener, Ricardo; Worm, M, Koç University Hospital, School of Medicine, Büyüktiryaki, Ayşe Betül (ORCID 0000-0003-1206-969X & YÖK ID 195944); Göncü, Özgür Emek Kocatürk (ORCID 0000-0003-2801-0959 & YÖK ID 217219); Saçkesen, Cansın (ORCID 0000-0002-1115-9805 & YÖK ID 182537), Zuberbier, Torsten; Abdul Latiff, Amir; Aggelidis, Xenofon; Augustin, Matthias; Balan, Radu-Gheorghe; Bangert, Christine; Beck, Lisa; Bieber, Thomas; Bernstein, Jonathan A.; Bertolin Colilla, Marta; Berardi, Alejandro; Bedbrook, Anna; Bindslev-Jensen, Carsten; Bousquet, Jean; de Bruin-Weller, Marjolein; Bruscky, Dayanne; Canonica, Giorgio Walter; Castro, Carla; Chanturidze, Natia; Chong-Neto, Herberto Jose; Chu, Chia-Yu; Chularojanamontri, Leena; Cork, Michael; Criado, Roberta F. J.; Barredo, Laia Curto; Custovic, Adnan; Darsow, Ulf; Emurlai, Arben; de Pablo, Ana; Del Giacco, Stefano; Girolomoni, Giampiero; Deleva Jovanova, Tanja; Deleuran, Mette; Douladiris, Nikolaos; Duarte, Bruno; Dubakiene, Ruta; Eller, Esben; Engel-Yeger, Batya; Ensina, Luis Felipe; Rosario Filho, Nelson; Flohr, Carsten; Fomina, Daria; Francuzik, Wojciech; Galimberti, Maria Laura; Gimenez-Arnau, Ana M.; Godse, Kiran; Mortz, Charlotte Gotthard; Gotua, Maia; Hide, Michihiro; Hoetzenecker, Wolfram; Hunzelmann, Nicolas; Irvine, Alan; Jack, Carolyn; Kanavarou, Ioanna; Katoh, Norito; Kinaciyan, Tamar; Kulthanan, Kanokvalai; Lapeere, Hilde; Lau, Susanne; Machado Forti Nastri, Mariana; Makris, Michael; Mansour, Eli; Marsland, Alexander; Morelo Rocha Felix, Mara; Moschione Castro, Ana Paula; Nettis, Eustachio; Nicolas, J. F.; Nosbaum, Audrey; Odemyr, Mikaela; Papapostolou, Niki; Parisi, Claudio A. S.; Paudel, Sushil; Peter, Jonny; Pokharel, Prakash; Puig, Luis; Quint, Tamara; Ramon, German Dario; Regateiro, Frederico; Ricci, Giampaolo; Rosario, Cristine; Schmid-Grendelmeier, Peter; Serra-Baldrich, Esther; Siemens, Kristina; Smith, Cathrine; Staubach, Petra; Stevanovic, Katarina; Su-Kucuk, Ozlem; Sussman, Gordon; Tavecchio, Simona; Teovska Mitrevska, Natasa; Thaci, Diamant; Toubi, Elias; Traidl-Hoffmann, Claudia; Treudler, Regina; Vadasz, Zahava; van Hofman, Ingrid; Ventura, Maria Teresa; Wang, Zhao; Werfel, Thomas; Wollenberg, Andreas; Yang, Ariana; Weng Yew, Yik; Zhao, Zuotao; Zwiener, Ricardo; Worm, M, Koç University Hospital, and School of Medicine

Abstract

Introduction: The integrated care pathways for atopic dermatitis (AD-ICPs) aim to bridge the gap between existing AD treatment evidence-based guidelines and expert opinion based on daily practice by offering a structured multidisciplinary plan for patient management of AD. ICPs have the potential to enhance guideline recommendations by combining interventions and aspects from different guidelines, integrating quality assurance, and describing co-ordination of care. Most importantly, patients can enter the ICPs at any level depending on AD severity, resources available in their country, and economic factors such as differences in insurance reimbursement systems.Methods: The GA(2)LEN ADCARE network and partners as well as all stakeholders, abbreviated as the AD-ICPs working group, were involved in the discussion and preparation of the AD ICPs during a series of subgroup workshops and meetings in years 2020 and 2021, after which the document was circulated within all GAL(2)EN ADCARE centres.Results: The AD-ICPs outline the diagnostic procedures, possible co-morbidities, different available treatment options including differential approaches for the pediatric population, and the role of the pharmacists and other stakeholders, as well as remaining unmet needs in the management of AD.Conclusion: The AD-ICPs provide a multidisciplinary plan for improved diagnosis, treatment, and patient feedback in AD management, as well as addressing critical unmet needs, including improved access to care, training specialists, implementation of educational programs, assessment on the impact of climate change, and fostering a personalised treatment approach. By focusing on these key areas, the initiative aims to pave the way for a brighter future in the management of AD., We thank the industry partners from the companies Almirall, AbbVie, Galderma, Novartis, Sanofi, and Thermo Fisher for taking part in the discussion on the atopic dermatitis-Integrated Care Pathways development during the AD-ICPs working group meetings. Open Access funding enabled and organized by Projekt DEAL.

Published
2023

12. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions : A GA(2)LEN position paper

Author

Zuberbier, Torsten, Doerr, Tamara, Aberer, Werner, Alvaro, Montserrat, Angier, Elizabeth, Arasi, Stefania, Arshad, Hasan, Ballmer-Weber, Barbara, Bartra, Joan, Beck, Lisa, Begin, Philippe, Bindslev-Jensen, Carsten, Bislimovska, Jovanka, Bousquet, Jean, Brockow, Knut, Bush, Andrew, Cianferoni, Antonella, Cork, Michael J., Custovic, Adnan, Darsow, Ulf, Jong, Nicolette, Deleanu, Diana, Del Giacco, Stefano, Deschildre, Antoine, Galvin, Audrey Dunn, Ebisawa, Motohiro, Fernandez-Rivas, Montserrat, Ferrer, Marta, Fiocchi, Alessandro, van Wijk, Roy Gerth, Gotua, Maia, Grimshaw, Kate, Gruenhagen, Josefine, Heffler, Enrico, Hide, Michihiro, Hoffmann-Sommergruber, Karin, Incorvaia, Cristoforo, Janson, Christer, John, Swen Malte, Jones, Carla, Jutel, Marek, Katoh, Norito, Kendziora, Benjamin, Kinaciyan, Tamar, Knol, Edward, Kurbacheva, Oksana, Lau, Susanne, Loh, Richard, Lombardi, Carlo, Makela, Mika, Marchisotto, Mary Jane, Makris, Michael, Maurer, Marcus, Meyer, Rosan, Mijakoski, Dragan, Minov, Jordan, Mullol, Joaquim, Nilsson, Caroline, Nowak-Wegrzyn, Anna, Nwaru, Bright, I, Odemyr, Mikela, Pajno, Giovanni Battista, Paudel, Sushil, Papadopoulos, Nikolaos G., Renz, Harald, Ricci, Giampaolo, Ring, Johannes, Rogala, Barbara, Sampson, Hugh, Senna, Gianenrico, Sitkauskiene, Brigita, Smith, Peter Kenneth, Stevanovic, Katarina, Stoleski, Sasho, Szajewska, Hania, Tanaka, Akio, Todo-Bom, Ana, Topal, Fatih Alexander, Valovirta, Erkka, Van Ree, Ronald, Venter, Carina, Woehrl, Stefan, Wong, Gary W. K., Zhao, Zuotao, Worm, Margitta, Zuberbier, Torsten, Doerr, Tamara, Aberer, Werner, Alvaro, Montserrat, Angier, Elizabeth, Arasi, Stefania, Arshad, Hasan, Ballmer-Weber, Barbara, Bartra, Joan, Beck, Lisa, Begin, Philippe, Bindslev-Jensen, Carsten, Bislimovska, Jovanka, Bousquet, Jean, Brockow, Knut, Bush, Andrew, Cianferoni, Antonella, Cork, Michael J., Custovic, Adnan, Darsow, Ulf, Jong, Nicolette, Deleanu, Diana, Del Giacco, Stefano, Deschildre, Antoine, Galvin, Audrey Dunn, Ebisawa, Motohiro, Fernandez-Rivas, Montserrat, Ferrer, Marta, Fiocchi, Alessandro, van Wijk, Roy Gerth, Gotua, Maia, Grimshaw, Kate, Gruenhagen, Josefine, Heffler, Enrico, Hide, Michihiro, Hoffmann-Sommergruber, Karin, Incorvaia, Cristoforo, Janson, Christer, John, Swen Malte, Jones, Carla, Jutel, Marek, Katoh, Norito, Kendziora, Benjamin, Kinaciyan, Tamar, Knol, Edward, Kurbacheva, Oksana, Lau, Susanne, Loh, Richard, Lombardi, Carlo, Makela, Mika, Marchisotto, Mary Jane, Makris, Michael, Maurer, Marcus, Meyer, Rosan, Mijakoski, Dragan, Minov, Jordan, Mullol, Joaquim, Nilsson, Caroline, Nowak-Wegrzyn, Anna, Nwaru, Bright, I, Odemyr, Mikela, Pajno, Giovanni Battista, Paudel, Sushil, Papadopoulos, Nikolaos G., Renz, Harald, Ricci, Giampaolo, Ring, Johannes, Rogala, Barbara, Sampson, Hugh, Senna, Gianenrico, Sitkauskiene, Brigita, Smith, Peter Kenneth, Stevanovic, Katarina, Stoleski, Sasho, Szajewska, Hania, Tanaka, Akio, Todo-Bom, Ana, Topal, Fatih Alexander, Valovirta, Erkka, Van Ree, Ronald, Venter, Carina, Woehrl, Stefan, Wong, Gary W. K., Zhao, Zuotao, and Worm, Margitta

Abstract

Background Food anaphylaxis is commonly elicited by unintentional ingestion of foods containing the allergen above the tolerance threshold level of the individual. While labeling the 14 main allergens used as ingredients in food products is mandatory in the EU, there is no legal definition of declaring potential contaminants. Precautionary allergen labeling such as "may contain traces of" is often used. However, this is unsatisfactory for consumers as they get no information if the contamination is below their personal threshold. In discussions with the food industry and technologists, it was suggested to use a voluntary declaration indicating that all declared contaminants are below a threshold of 0.5 mg protein per 100 g of food. This concentration is known to be below the threshold of most patients, and it can be technically guaranteed in most food production. However, it was also important to assess that in case of accidental ingestion of contaminants below this threshold by highly allergic patients, no fatal anaphylactic reaction could occur. Therefore, we performed a systematic review to assess whether a fatal reaction to 5mg of protein or less has been reported, assuming that a maximum portion size of 1kg of a processed food exceeds any meal and thus gives a sufficient safety margin. Methods MEDLINE and EMBASE were searched until 24 January 2021 for provocation studies and case reports in which one of the 14 major food allergens was reported to elicit fatal or life-threatening anaphylactic reactions and assessed if these occurred below the ingestion of 5mg of protein. A Delphi process was performed to obtain an expert consensus on the results. Results In the 210 studies included, in our search, no reports of fatal anaphylactic reactions reported below 5 mg protein ingested were identified. However, in provocation studies and case reports, severe reactions below 5 mg were reported for the following allergens: eggs, fish, lupin, milk, nuts, peanuts, soy, and se

Published
2022
Full Text
View/download PDF

13. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions:A GA²LEN position paper

Author

Zuberbier, Torsten, Dörr, Tamara, Aberer, Werner, Alvaro, Montserrat, Angier, Elizabeth, Arasi, Stefania, Arshad, Hasan, Ballmer-Weber, Barbara, Bartra, Joan, Beck, Lisa, Bégin, Philippe, Bindslev-Jensen, Carsten, Bislimovska, Jovanka, Bousquet, Jean, Brockow, Knut, Bush, Andrew, Cianferoni, Antonella, Cork, Michael J., Custovic, Adnan, Darsow, Ulf, de Jong, Nicolette, Deleanu, Diana, Del Giacco, Stefano, Deschildre, Antoine, Dunn Galvin, Audrey, Ebisawa, Motohiro, Fernández-Rivas, Montserrat, Ferrer, Marta, Fiocchi, Alessandro, Gerth van Wijk, Roy, Gotua, Maia, Grimshaw, Kate, Grünhagen, Josefine, Heffler, Enrico, Hide, Michihiro, Hoffmann-Sommergruber, Karin, Incorvaia, Cristoforo, Janson, Christer, Malte John, Swen, Jones, Carla, Jutel, Marek, Katoh, Norito, Kendziora, Benjamin, Kinaciyan, Tamar, Knol, Edward, Kurbacheva, Oksana, Lau, Susanne, Loh, Richard, Lombardi, Carlo, Mäkelä, Mika, Marchisotto, Mary Jane, Makris, Michael, Maurer, Marcus, Meyer, Rosan, Mijakoski, Dragan, Minov, Jordan, Mullol, Joaquim, Nilsson, Caroline, Nowak–Wegrzyn, Anna, Nwaru, Bright I., Odemyr, Mikela, Pajno, Giovanni Battista, Paudel, Sushil, Papadopoulos, Nikolaos G., Renz, Harald, Ricci, Giampaolo, Ring, Johannes, Rogala, Barbara, Sampson, Hugh, Senna, Gianenrico, Sitkauskiene, Brigita, Smith, Peter Kenneth, Stevanovic, Katarina, Stoleski, Sasho, Szajewska, Hania, Tanaka, Akio, Todo-Bom, Ana, Topal, Fatih Alexander, Valovirta, Erkka, Van Ree, Ronald, Venter, Carina, Wöhrl, Stefan, Wong, Gary W.K., Zhao, Zuotao, Worm, Margitta, Zuberbier, Torsten, Dörr, Tamara, Aberer, Werner, Alvaro, Montserrat, Angier, Elizabeth, Arasi, Stefania, Arshad, Hasan, Ballmer-Weber, Barbara, Bartra, Joan, Beck, Lisa, Bégin, Philippe, Bindslev-Jensen, Carsten, Bislimovska, Jovanka, Bousquet, Jean, Brockow, Knut, Bush, Andrew, Cianferoni, Antonella, Cork, Michael J., Custovic, Adnan, Darsow, Ulf, de Jong, Nicolette, Deleanu, Diana, Del Giacco, Stefano, Deschildre, Antoine, Dunn Galvin, Audrey, Ebisawa, Motohiro, Fernández-Rivas, Montserrat, Ferrer, Marta, Fiocchi, Alessandro, Gerth van Wijk, Roy, Gotua, Maia, Grimshaw, Kate, Grünhagen, Josefine, Heffler, Enrico, Hide, Michihiro, Hoffmann-Sommergruber, Karin, Incorvaia, Cristoforo, Janson, Christer, Malte John, Swen, Jones, Carla, Jutel, Marek, Katoh, Norito, Kendziora, Benjamin, Kinaciyan, Tamar, Knol, Edward, Kurbacheva, Oksana, Lau, Susanne, Loh, Richard, Lombardi, Carlo, Mäkelä, Mika, Marchisotto, Mary Jane, Makris, Michael, Maurer, Marcus, Meyer, Rosan, Mijakoski, Dragan, Minov, Jordan, Mullol, Joaquim, Nilsson, Caroline, Nowak–Wegrzyn, Anna, Nwaru, Bright I., Odemyr, Mikela, Pajno, Giovanni Battista, Paudel, Sushil, Papadopoulos, Nikolaos G., Renz, Harald, Ricci, Giampaolo, Ring, Johannes, Rogala, Barbara, Sampson, Hugh, Senna, Gianenrico, Sitkauskiene, Brigita, Smith, Peter Kenneth, Stevanovic, Katarina, Stoleski, Sasho, Szajewska, Hania, Tanaka, Akio, Todo-Bom, Ana, Topal, Fatih Alexander, Valovirta, Erkka, Van Ree, Ronald, Venter, Carina, Wöhrl, Stefan, Wong, Gary W.K., Zhao, Zuotao, and Worm, Margitta

Abstract

Background: Food anaphylaxis is commonly elicited by unintentional ingestion of foods containing the allergen above the tolerance threshold level of the individual. While labeling the 14 main allergens used as ingredients in food products is mandatory in the EU, there is no legal definition of declaring potential contaminants. Precautionary allergen labeling such as “may contain traces of” is often used. However, this is unsatisfactory for consumers as they get no information if the contamination is below their personal threshold. In discussions with the food industry and technologists, it was suggested to use a voluntary declaration indicating that all declared contaminants are below a threshold of 0.5 mg protein per 100 g of food. This concentration is known to be below the threshold of most patients, and it can be technically guaranteed in most food production. However, it was also important to assess that in case of accidental ingestion of contaminants below this threshold by highly allergic patients, no fatal anaphylactic reaction could occur. Therefore, we performed a systematic review to assess whether a fatal reaction to 5mg of protein or less has been reported, assuming that a maximum portion size of 1kg of a processed food exceeds any meal and thus gives a sufficient safety margin. Methods: MEDLINE and EMBASE were searched until 24 January 2021 for provocation studies and case reports in which one of the 14 major food allergens was reported to elicit fatal or life-threatening anaphylactic reactions and assessed if these occurred below the ingestion of 5mg of protein. A Delphi process was performed to obtain an expert consensus on the results. Results: In the 210 studies included, in our search, no reports of fatal anaphylactic reactions reported below 5 mg protein ingested were identified. However, in provocation studies and case reports, severe reactions below 5 mg were reported for the following allergens: eggs, fish, lupin, milk, nuts, peanuts, soy

Published
2022

14. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

Author

CTI Research, MS Dermatologie/Allergologie, Infection & Immunity, Zuberbier, Torsten, Dörr, Tamara, Aberer, Werner, Alvaro, Montserrat, Angier, Elizabeth, Arasi, Stefania, Arshad, Hasan, Ballmer-Weber, Barbara, Bartra, Joan, Beck, Lisa, Bégin, Philippe, Bindslev-Jensen, Carsten, Bislimovska, Jovanka, Bousquet, Jean, Brockow, Knut, Bush, Andrew, Cianferoni, Antonella, Cork, Michael J, Custovic, Adnan, Darsow, Ulf, de Jong, Nicolette, Deleanu, Diana, Del Giacco, Stefano, Deschildre, Antoine, Dunn Galvin, Audrey, Ebisawa, Motohiro, Fernández-Rivas, Montserrat, Ferrer, Marta, Fiocchi, Alessandro, Gerth van Wijk, Roy, Gotua, Maia, Grimshaw, Kate, Grünhagen, Josefine, Heffler, Enrico, Hide, Michihiro, Hoffmann-Sommergruber, Karin, Incorvaia, Cristoforo, Janson, Christer, Malte John, Swen, Jones, Carla, Jutel, Marek, Katoh, Norito, Kendziora, Benjamin, Kinaciyan, Tamar, Knol, Edward, Kurbacheva, Oksana, Lau, Susanne, Loh, Richard, Lombardi, Carlo, Mäkelä, Mika, Marchisotto, Mary Jane, Makris, Michael, Maurer, Marcus, Meyer, Rosan, Mijakoski, Dragan, Minov, Jordan, Mullol, Joaquim, Nilsson, Caroline, Nowak-Wegrzyn, Anna, Nwaru, Bright I, Odemyr, Mikela, Pajno, Giovanni Battista, Paudel, Sushil, Papadopoulos, Nikolaos G, Renz, Harald, Ricci, Giampaolo, Ring, Johannes, Rogala, Barbara, Sampson, Hugh, Senna, Gianenrico, Sitkauskiene, Brigita, Smith, Peter Kenneth, Stevanovic, Katarina, Stoleski, Sasho, Szajewska, Hania, Tanaka, Akio, Todo-Bom, Ana, Topal, Fatih Alexander, Valovirta, Erkka, Van Ree, Ronald, Venter, Carina, Wöhrl, Stefan, Wong, Gary W K, Zhao, Zuotao, Worm, Margitta, CTI Research, MS Dermatologie/Allergologie, Infection & Immunity, Zuberbier, Torsten, Dörr, Tamara, Aberer, Werner, Alvaro, Montserrat, Angier, Elizabeth, Arasi, Stefania, Arshad, Hasan, Ballmer-Weber, Barbara, Bartra, Joan, Beck, Lisa, Bégin, Philippe, Bindslev-Jensen, Carsten, Bislimovska, Jovanka, Bousquet, Jean, Brockow, Knut, Bush, Andrew, Cianferoni, Antonella, Cork, Michael J, Custovic, Adnan, Darsow, Ulf, de Jong, Nicolette, Deleanu, Diana, Del Giacco, Stefano, Deschildre, Antoine, Dunn Galvin, Audrey, Ebisawa, Motohiro, Fernández-Rivas, Montserrat, Ferrer, Marta, Fiocchi, Alessandro, Gerth van Wijk, Roy, Gotua, Maia, Grimshaw, Kate, Grünhagen, Josefine, Heffler, Enrico, Hide, Michihiro, Hoffmann-Sommergruber, Karin, Incorvaia, Cristoforo, Janson, Christer, Malte John, Swen, Jones, Carla, Jutel, Marek, Katoh, Norito, Kendziora, Benjamin, Kinaciyan, Tamar, Knol, Edward, Kurbacheva, Oksana, Lau, Susanne, Loh, Richard, Lombardi, Carlo, Mäkelä, Mika, Marchisotto, Mary Jane, Makris, Michael, Maurer, Marcus, Meyer, Rosan, Mijakoski, Dragan, Minov, Jordan, Mullol, Joaquim, Nilsson, Caroline, Nowak-Wegrzyn, Anna, Nwaru, Bright I, Odemyr, Mikela, Pajno, Giovanni Battista, Paudel, Sushil, Papadopoulos, Nikolaos G, Renz, Harald, Ricci, Giampaolo, Ring, Johannes, Rogala, Barbara, Sampson, Hugh, Senna, Gianenrico, Sitkauskiene, Brigita, Smith, Peter Kenneth, Stevanovic, Katarina, Stoleski, Sasho, Szajewska, Hania, Tanaka, Akio, Todo-Bom, Ana, Topal, Fatih Alexander, Valovirta, Erkka, Van Ree, Ronald, Venter, Carina, Wöhrl, Stefan, Wong, Gary W K, Zhao, Zuotao, and Worm, Margitta

Published
2022

15. The characterization of LINE-1 elements in the human placenta and their role in preeclampsia

Author

Stevanovic, Katarina

Subjects
Long interspersed nuclear elements (LINE-1), microRNA (miRNA), Transposable elements (TE), 500 Natural sciences and mathematics::570 Life sciences::572 Biochemistry, Placenta, Pre-eclampsia (PE), Trophoblasts
Abstract

Long interspersed nuclear elements (LINE-1), a type of retrotransposon, are genetic elements in the human genome that can self-amplify and integrate back into the genome, increasing their copy number. Their mode of action is called retrotransposition, and it is known to affect the human genome in many ways: generating insertional mutations, genomic instability, alterations in gene expression, and contribute to genetic innovation. These elements are usually silenced in somatic tissue because of their mutagenic potential. I have identified that the evolutionary youngest and human-specific LINE-1 elements are expressed and active in human placental trophoblast cells and that LINE-1 elements are over-expressed and possibly over-active in certain patients of the pregnancy disorder pre-eclampsia (PE). PE is a pregnancy-specific complex disorder in which a combination of poor placentation and placental stress leads to hypertension and proteinuria in the mother following the 20th week of gestation. PE affects 2-8% of all pregnancies. Despite PE being the leading cause of maternal and neonatal mortality and morbidity, the etiology remains unknown. One major problem in PE research is that PE is a multi origin disorder, exhibiting different phenotypes before the onset of the disease. I hypothesized that LINE-1 overexpression and activity in an immune-mediated subtype of PE patients contributes to PE pathogenesis. I conducted RNA sequencing in 10 PE and 8 control primary human trophoblast and have identified that human-specific LINE-1 elements, L1HS, are over expressed in 3/10 patients. Using RT-PCR, western blot, and immunohistochemistry methods, I have shown that LINE1s are expressed in primary human trophoblasts at the RNA and protein levels and in all three subtypes of trophoblast cells. Using a LINE-1 retrotransposition reporter assay, I showed that trophoblast cells contain all the necessary conditions to support LINE-1 retrotransposition and that there is greater retrotransposition activity in the PE-model trophoblast cell line. In addition, I identified that LINE-1 over expression in a subset of PE patients induces the expression innate immune response, suggesting a mechanism of early pathogenesis induction in a subtype of PE patients. Lastly, I also showed that in PE, a TE-derived miRNA, has-miR-576-5p, is upregulated, among other newly discovered dyregulated miRNAs. The expression of placenta fuction-relevant genes that are predicted targets of has-miR-576-5p was investigated, but no dysregulation was determined. Overall, this research revealed novel information about the somatic expression and activity of LINE-1 in the human placenta, and for the first time provided insight into the potential role of LINE-1 in PE pathogenesis.

Published
2022
Full Text
View/download PDF

16. Ga²len adcare - responding to the need for ongoing education in atopic dermatitis for healthcare providers globally and currently in South Africa

Author

Hofman, Ingrid van, Stevanovic, Katarina, Meesch, Cathrin, Muraro, Antonella M., Papadopoulos, N.G., Maurer, Marcus, Bindslev-Jensen, Carsten, Peter, Jonny G., Canonica, Walter G., Zuberbier, Torsten, and Publica

Subjects
education, GA²LEN ADCARE, atopic dermatitis, alopecia areata, training programme
Abstract

Effective continuing education in dermatology for healthcare providers can be supported by various measures such as literature, webinars, online tools and lectures. The Global Allergy and Asthma European Network (GA²LEN) has developed a compact training programme on allergic diseases, including but not limited to atopic dermatitis, alopecia areata, allergic rhinitis, asthma, pruritus, angioedema, urticaria and anaphylaxis and food allergy. In this article we present the impact of and argue for the continuing need for GA2LEN training programmes on the basis of a review of data from the past six global educational programmes. These data indicate the efficacy of ongoing education and the updating of healthcare professionals’ knowledge and the need for continuing education in South Africa.

Published
2022

18. Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs.

Author

Zuberbier, Torsten, Beck, Lisa A., Bedbrook, Anna, de Bruin‐Weller, Marjolein, Bousquet, Jean, Cork, Michael, Douladiris, Nikolaos, Katoh, Norito, Mortz, Charlotte G., Werfel, Thomas, Wojciech, Francuzik, Wollenberg, Andreas, Siemens, Kristina, Stevanovic, Katarina, and Worm, Margitta

Subjects
ATOPIC dermatitis, INTEGRATIVE medicine, MEDICAL personnel, MEDICAL protocols, ADULT education workshops
Abstract

Background: GA2LEN‐ADCARE is a branch of the largest multidisciplinary network of research centres and clinical care in allergy and asthma, GA2LEN, focussing on the field of atopic dermatitis (AD). AD is a chronic inflammatory skin disease with high burden and many comorbidities requiring different levels of treatment. The need for aligned information from all involved healthcare providers led to the discussion of an integrated care pathway (ICP) plan for AD patient care involving all stakeholders and considering the complexity and variability of the disease, with a particular focus placed on the large number of patients with milder forms of AD. Methods: The GA2LEN ADCARE network and all stakeholders, abbreviated the AD‐ICPs working group, were involved in the discussion and preparation of the AD‐ICPs during a series of subgroup workshops and meetings in years 2020 and 2021. Results: Here we discuss the unmet needs in AD, the methodology for devising an AD‐ICP and the ICP action plan. Conclusion: The GA2LEN ADCARE network has outlined the unmet needs in AD and provided an action plan for devising AD‐ICPs, considering the complexity and variability of the disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

19. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food—A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper

Author

Zuberbier, Torsten, primary, Dörr, Tamara, additional, Aberer, Werner, additional, Alvaro, Montserrat, additional, Angier, Elizabeth, additional, Arasi, Stefania, additional, Arshad, Hasan, additional, Ballmer‐Weber, Barbara, additional, Bartra, Joan, additional, Beck, Lisa, additional, Bégin, Philippe, additional, Bindslev‐Jensen, Carsten, additional, Bislimovska, Jovanka, additional, Bousquet, Jean, additional, Brockow, Knut, additional, Bush, Andrew, additional, Cianferoni, Antonella, additional, Cork, Michael J., additional, Custovic, Adnan, additional, Darsow, Ulf, additional, Jong, Nicolette, additional, Deleanu, Diana, additional, Del Giacco, Stefano, additional, Deschildre, Antoine, additional, Dunn Galvin, Audrey, additional, Ebisawa, Motohiro, additional, Fernández‐Rivas, Montserrat, additional, Ferrer, Marta, additional, Fiocchi, Alessandro, additional, Gerth van Wijk, Roy, additional, Gotua, Maia, additional, Grimshaw, Kate, additional, Grünhagen, Josefine, additional, Heffler, Enrico, additional, Hide, Michihiro, additional, Hoffmann‐Sommergruber, Karin, additional, Incorvaia, Cristoforo, additional, Janson, Christer, additional, Malte John, Swen, additional, Jones, Carla, additional, Jutel, Marek, additional, Katoh, Norito, additional, Kendziora, Benjamin, additional, Kinaciyan, Tamar, additional, Knol, Edward, additional, Kurbacheva, Oksana, additional, Lau, Susanne, additional, Loh, Richard, additional, Lombardi, Carlo, additional, Mäkelä, Mika, additional, Marchisotto, Mary Jane, additional, Makris, Michael, additional, Maurer, Marcus, additional, Meyer, Rosan, additional, Mijakoski, Dragan, additional, Minov, Jordan, additional, Mullol, Joaquim, additional, Nilsson, Caroline, additional, Nowak–Wegrzyn, Anna, additional, Nwaru, Bright I., additional, Odemyr, Mikela, additional, Pajno, Giovanni Battista, additional, Paudel, Sushil, additional, Papadopoulos, Nikolaos G., additional, Renz, Harald, additional, Ricci, Giampaolo, additional, Ring, Johannes, additional, Rogala, Barbara, additional, Sampson, Hugh, additional, Senna, Gianenrico, additional, Sitkauskiene, Brigita, additional, Smith, Peter Kenneth, additional, Stevanovic, Katarina, additional, Stoleski, Sasho, additional, Szajewska, Hania, additional, Tanaka, Akio, additional, Todo‐Bom, Ana, additional, Topal, Fatih Alexander, additional, Valovirta, Erkka, additional, Van Ree, Ronald, additional, Venter, Carina, additional, Wöhrl, Stefan, additional, Wong, Gary W.K., additional, Zhao, Zuotao, additional, and Worm, Margitta, additional

Published
2021
Full Text
View/download PDF

22. Role of IL‐17 in atopy—A systematic review

Author

Hofmann, Maja A., Fluhr, Joachim W., Ruwwe‐Glösenkamp, Christoph, Stevanovic, Katarina, Bergmann, Karl‐Christian, and Zuberbier, Torsten

Subjects
Atopie, IL-17, Überempfindlichkeit, atopische Dermatitis, IL‐17, allergische Erkrankung, Review, Immunologic diseases. Allergy, RC581-607, 600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
Abstract

Purpose of Review Atopy is defined as the genetic predisposition to react with type I allergic diseases such as food‐, skin‐, and respiratory allergies. Distinct molecular mechanisms have been described, including the known Th2 driven immune response. IL‐17A (IL‐17) is mainly produced by Th17 cells and belongs to the IL‐17 family of cytokines, IL‐17A to F. While IL‐17 plays a major role in inflammatory and autoimmune disorders, more data was published in recent years elucidating the role of IL‐17 in allergic diseases. The present study aimed to elaborate specifically the role of IL‐17 in atopy. Methods A systematic literature search was conducted in MEDLINE, Embase, and Cochrane Central Register of Controlled Trials, regarding IL‐17 and atopy/allergic diseases. Results In total, 31 novel publications could be identified (food allergy n = 3, allergic asthma n = 7, allergic rhinitis [AR] n = 10, atopic dermatitis [AD] n = 11). In all allergic diseases, the IL‐17 pathway has been investigated. Serum IL‐17 was elevated in all allergic diseases. In AR, serum and nasal IL‐17 levels correlated with the severity of the disease. In food allergies, serum IL‐17E was also elevated in children. In AD, there is a trend for higher IL‐17 values in the serum and skin specimen, while it is more expressed in acute lesions. In allergic asthma, serum IL‐17 levels were increased. In two studies, higher serum IL‐17 levels were found in severe persistent asthmatic patients than in intermittent asthmatics or healthy controls. Only one therapeutic clinical study exists on allergic diseases (asthma patients) using a monoclonal antibody against the IL‐17 receptor A. No clinical efficacy was found in the total study population, except for a subgroup of patients with (post‐bronchodilator) high reversibility. Summary The role of IL 17 in the pathogenesis of allergic diseases is evident, but the involvement of the Th17 cytokine in the pathophysiological pathway is not conclusively defined. IL‐17 is most likely relevant and will be a clinical target in subgroups of patients. The current data indicates that IL‐17 is elevated more often in acute and severe forms of allergic diseases.

Published
2021
Full Text
View/download PDF

23. GA²LEN ADCARE -- RESPONDING TO THE NEED FOR ONGOING EDUCATION IN ATOPIC DERMATITIS FOR HEALTHCARE PROVIDERS GLOBALLY AND CURRENTLY IN SOUTH AFRICA.

Author

van Hofman, Ingrid, Stevanovic, Katarina, Meesch, Cathrin, Muraro, Antonella, Papadopoulos, Nikolaos G., Maurer, Marcus, Bindslev-Jensen, Carsten, Peter, Jonny, Canonica, Giorgio Walter, and Zuberbier, Torsten

Subjects
*ATOPIC dermatitis, *PATIENT education, *ALLERGIES, *ALOPECIA areata
Abstract

Effective continuing education in dermatology for healthcare providers can be supported by various measures such as literature, webinars, online tools and lectures. The Global Allergy and Asthma European Network (GA²LEN) has developed a compact training programme on allergic diseases, including but not limited to atopic dermatitis, alopecia areata, allergic rhinitis, asthma, pruritus, angioedema, urticaria and anaphylaxis and food allergy. In this article we present the impact of and argue for the continuing need for GA²LEN training programmes on the basis of a review of data from the past six global educational programmes. These data indicate the efficacy of ongoing education and the updating of healthcare professionals' knowledge and the need for continuing education in South Africa. [ABSTRACT FROM AUTHOR]

Published
2022

30. GA 2 LEN ANACARE consensus statement: Potential of omalizumab in food allergy management.

Author

Zuberbier T, Muraro A, Nurmatov U, Arasi S, Stevanovic K, Anagnostou A, Bonaguro R, Chinthrajah S, Lack G, Fiocchi A, Le TM, Turner P, Lozano MA, Angier E, Barni S, Bégin P, Ballmer-Weber B, Cardona V, Bindslev-Jensen C, Cianferoni A, de Jong N, de Silva D, Deschildre A, Galvin AD, Ebisawa M, Fleischer DM, Gerdts J, Giovannini M, Gradman J, Halken S, Arshad SH, Khaleva E, Lau S, Loh R, Mäkelä MJ, Marchisotto MJ, Morandini L, Mortz CG, Nilsson C, Nowak-Wegrzyn A, Podestà M, Poulsen LK, Roberts G, Rodríguez Del Río P, Sampson HA, Sánchez A, Schnadt S, Smith PK, Szajewska H, Mitrevska NT, Toniolo A, Venter C, Warner A, Wong GWK, Wood R, and Worm M

Abstract

Immunoglobulin E (IgE)-mediated food allergies are the most common type of food allergy, often causing rapid symptoms after exposure to allergens posing a serious health risk and a high impact on patient's and caregiver's quality of life. Omalizumab, a humanized anti-IgE monoclonal antibody, reduces allergic reactions by binding to circulating IgE. Omalizumab has been successfully used in allergic asthma, chronic rhinosinusitis with nasal polyps, and chronic urticaria, and was recently approved for treating IgE-mediated food allergies by the US Food and Drug Administration (FDA). This GA 2 LEN ANACARE Consensus Statement presents our position on the use of omalizumab for treating IgE-mediated food allergies, based on a systematic review and meta-analysis, experience with use for other conditions, and expert consensus achieved via an eDelphi process. Following publication of the recent OUtMATCH study (stage 1) results and subsequent FDA approval, we propose that there is now sufficient evidence to recommend omalizumab as the only drug currently available that can mechanistically reduce IgE-mediated food allergic reactions. We acknowledge that the evidence does not reach the highest level of evidence which would be needed for a guideline recommendation., (© 2024 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.)

Published
2024
Full Text
View/download PDF

31. A concept for integrated care pathways for atopic dermatitis-A GA 2 LEN ADCARE initiative.

Author

Zuberbier T, Abdul Latiff A, Aggelidis X, Augustin M, Balan RG, Bangert C, Beck L, Bieber T, Bernstein JA, Bertolin Colilla M, Berardi A, Bedbrook A, Bindslev-Jensen C, Bousquet J, de Bruin-Weller M, Bruscky D, Buyuktiryaki B, Canonica GW, Castro C, Chanturidze N, Chong-Neto HJ, Chu CY, Chularojanamontri L, Cork M, Criado RFJ, Barredo LC, Custovic A, Darsow U, Emurlai A, de Pablo A, Del Giacco S, Girolomoni G, Deleva Jovanova T, Deleuran M, Douladiris N, Duarte B, Dubakiene R, Eller E, Engel-Yeger B, Ensina LF, Filho NR, Flohr C, Fomina D, Francuzik W, Galimberti ML, Giménez-Arnau AM, Godse K, Mortz CG, Gotua M, Hide M, Hoetzenecker W, Hunzelmann N, Irvine A, Jack C, Kanavarou I, Katoh N, Kinaciyan T, Kocatürk E, Kulthanan K, Lapeere H, Lau S, Machado Forti Nastri M, Makris M, Mansour E, Marsland A, Morelo Rocha Felix M, Moschione Castro AP, Nettis E, Nicolas JF, Nosbaum A, Odemyr M, Papapostolou N, Parisi CAS, Paudel S, Peter J, Pokharel P, Puig L, Quint T, Ramon GD, Regateiro F, Ricci G, Rosario C, Sackesen C, Schmid-Grendelmeier P, Serra-Baldrich E, Siemens K, Smith C, Staubach P, Stevanovic K, Su-Kücük Ö, Sussman G, Tavecchio S, Teovska Mitrevska N, Thaci D, Toubi E, Traidl-Hoffmann C, Treudler R, Vadasz Z, van Hofman I, Ventura MT, Wang Z, Werfel T, Wollenberg A, Yang A, Weng Yew Y, Zhao Z, Zwiener R, and Worm M

Abstract

Introduction: The integrated care pathways for atopic dermatitis (AD-ICPs) aim to bridge the gap between existing AD treatment evidence-based guidelines and expert opinion based on daily practice by offering a structured multidisciplinary plan for patient management of AD. ICPs have the potential to enhance guideline recommendations by combining interventions and aspects from different guidelines, integrating quality assurance, and describing co-ordination of care. Most importantly, patients can enter the ICPs at any level depending on AD severity, resources available in their country, and economic factors such as differences in insurance reimbursement systems., Methods: The GA 2 LEN ADCARE network and partners as well as all stakeholders, abbreviated as the AD-ICPs working group, were involved in the discussion and preparation of the AD ICPs during a series of subgroup workshops and meetings in years 2020 and 2021, after which the document was circulated within all GAL 2 EN ADCARE centres., Results: The AD-ICPs outline the diagnostic procedures, possible co-morbidities, different available treatment options including differential approaches for the pediatric population, and the role of the pharmacists and other stakeholders, as well as remaining unmet needs in the management of AD., Conclusion: The AD-ICPs provide a multidisciplinary plan for improved diagnosis, treatment, and patient feedback in AD management, as well as addressing critical unmet needs, including improved access to care, training specialists, implementation of educational programs, assessment on the impact of climate change, and fostering a personalised treatment approach. By focusing on these key areas, the initiative aims to pave the way for a brighter future in the management of AD., (© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.)

Published
2023
Full Text
View/download PDF

32. Proposal of 0.5 mg of protein/100 g of processed food as threshold for voluntary declaration of food allergen traces in processed food-A first step in an initiative to better inform patients and avoid fatal allergic reactions: A GA²LEN position paper.

Author

Zuberbier T, Dörr T, Aberer W, Alvaro M, Angier E, Arasi S, Arshad H, Ballmer-Weber B, Bartra J, Beck L, Bégin P, Bindslev-Jensen C, Bislimovska J, Bousquet J, Brockow K, Bush A, Cianferoni A, Cork MJ, Custovic A, Darsow U, de Jong N, Deleanu D, Del Giacco S, Deschildre A, Dunn Galvin A, Ebisawa M, Fernández-Rivas M, Ferrer M, Fiocchi A, Gerth van Wijk R, Gotua M, Grimshaw K, Grünhagen J, Heffler E, Hide M, Hoffmann-Sommergruber K, Incorvaia C, Janson C, Malte John S, Jones C, Jutel M, Katoh N, Kendziora B, Kinaciyan T, Knol E, Kurbacheva O, Lau S, Loh R, Lombardi C, Mäkelä M, Marchisotto MJ, Makris M, Maurer M, Meyer R, Mijakoski D, Minov J, Mullol J, Nilsson C, Nowak-Wegrzyn A, Nwaru BI, Odemyr M, Pajno GB, Paudel S, Papadopoulos NG, Renz H, Ricci G, Ring J, Rogala B, Sampson H, Senna G, Sitkauskiene B, Smith PK, Stevanovic K, Stoleski S, Szajewska H, Tanaka A, Todo-Bom A, Topal FA, Valovirta E, Van Ree R, Venter C, Wöhrl S, Wong GWK, Zhao Z, and Worm M

Subjects
Allergens analysis, Animals, Eggs, Food Labeling, Humans, Anaphylaxis diagnosis, Anaphylaxis etiology, Anaphylaxis prevention & control, Food Hypersensitivity diagnosis
Abstract

Background: Food anaphylaxis is commonly elicited by unintentional ingestion of foods containing the allergen above the tolerance threshold level of the individual. While labeling the 14 main allergens used as ingredients in food products is mandatory in the EU, there is no legal definition of declaring potential contaminants. Precautionary allergen labeling such as "may contain traces of" is often used. However, this is unsatisfactory for consumers as they get no information if the contamination is below their personal threshold. In discussions with the food industry and technologists, it was suggested to use a voluntary declaration indicating that all declared contaminants are below a threshold of 0.5 mg protein per 100 g of food. This concentration is known to be below the threshold of most patients, and it can be technically guaranteed in most food production. However, it was also important to assess that in case of accidental ingestion of contaminants below this threshold by highly allergic patients, no fatal anaphylactic reaction could occur. Therefore, we performed a systematic review to assess whether a fatal reaction to 5mg of protein or less has been reported, assuming that a maximum portion size of 1kg of a processed food exceeds any meal and thus gives a sufficient safety margin., Methods: MEDLINE and EMBASE were searched until 24 January 2021 for provocation studies and case reports in which one of the 14 major food allergens was reported to elicit fatal or life-threatening anaphylactic reactions and assessed if these occurred below the ingestion of 5mg of protein. A Delphi process was performed to obtain an expert consensus on the results., Results: In the 210 studies included, in our search, no reports of fatal anaphylactic reactions reported below 5 mg protein ingested were identified. However, in provocation studies and case reports, severe reactions below 5 mg were reported for the following allergens: eggs, fish, lupin, milk, nuts, peanuts, soy, and sesame seeds., Conclusion: Based on the literature studied for this review, it can be stated that cross-contamination of the 14 major food allergens below 0.5 mg/100 g is likely not to endanger most food allergic patients when a standard portion of food is consumed. We propose to use the statement "this product contains the named allergens in the list of ingredients, it may contain traces of other contaminations (to be named, e.g. nut) at concentrations less than 0.5 mg per 100 g of this product" for a voluntary declaration on processed food packages. This level of avoidance of cross-contaminations can be achieved technically for most processed foods, and the statement would be a clear and helpful message to the consumers. However, it is clearly acknowledged that a voluntary declaration is only a first step to a legally binding solution. For this, further research on threshold levels is encouraged., (© 2021 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results